HC Wainwright Analysts Boost Earnings Estimates for ARTV

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Analysts at HC Wainwright raised their Q1 2025 earnings estimates for Artiva Biotherapeutics in a note issued to investors on Wednesday, March 26th. HC Wainwright analyst E. White now expects that the company will post earnings of ($0.68) per share for the quarter, up from their previous forecast of ($0.76). HC Wainwright currently has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.95) per share. HC Wainwright also issued estimates for Artiva Biotherapeutics’ Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.77) EPS, FY2025 earnings at ($2.89) EPS, FY2026 earnings at ($3.44) EPS and FY2027 earnings at ($4.10) EPS.

Several other brokerages also recently weighed in on ARTV. Cantor Fitzgerald cut their price target on Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Tuesday, March 25th. Needham & Company LLC restated a “buy” rating and set a $23.00 target price on shares of Artiva Biotherapeutics in a research note on Tuesday, March 25th. Finally, Wedbush reiterated an “outperform” rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a research note on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $20.40.

Artiva Biotherapeutics Trading Down 10.7 %

Shares of NASDAQ ARTV opened at $3.16 on Friday. The business’s fifty day simple moving average is $4.71 and its 200-day simple moving average is $9.21. Artiva Biotherapeutics has a 12-month low of $3.15 and a 12-month high of $17.31.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets acquired a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth about $42,000. Charles Schwab Investment Management Inc. increased its stake in Artiva Biotherapeutics by 8.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 43,526 shares of the company’s stock valued at $439,000 after purchasing an additional 3,233 shares during the last quarter. Wells Fargo & Company MN raised its holdings in Artiva Biotherapeutics by 64.0% during the fourth quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock worth $87,000 after purchasing an additional 3,361 shares in the last quarter. Northern Trust Corp lifted its position in shares of Artiva Biotherapeutics by 3.8% during the 4th quarter. Northern Trust Corp now owns 117,112 shares of the company’s stock worth $1,180,000 after buying an additional 4,335 shares during the last quarter. Finally, Barclays PLC lifted its position in shares of Artiva Biotherapeutics by 23.2% during the 4th quarter. Barclays PLC now owns 24,161 shares of the company’s stock worth $244,000 after buying an additional 4,545 shares during the last quarter.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.